IntechOpen

Home > Authors and editors

Ayman Karkar

Baxter AG

Dr. Ayman Karkar, MBBS, MSc, PhD, MRCP, FRCP, FASN Baxter Head of Medical Affairs for Renal Care – Middle East & Africa Dr. Karkar is a consultant physician and Nephrologist and a Fellow of the Royal Colleges of Physicians (FRCP) of the United Kingdom (London, Edinburgh, Glasgow, and Ireland), the American National Kidney Foundation and the American Society of Nephrology. Following graduation from medical school, Dr. Karkar received his MSc in Nephology and Hypertension and PhD in Renal Medicine from the Hammersmith Hospital, University of London. Dr. Karkar has been a Consultant Physician and Nephrologist at the Kanoo Kidney Centre (KKC), Dammam Medical Complex (DMC), Ministry of Health (MoH), Saudi Arabia from 2001- 2014. He served as director of KKC and DMC in addition to supervising the renal services in Eastern Province, Saudi Arabia. He has served as a key advisor to the Saudi MoH, and a chairman and a member of numerous steering committees, where he provided valuable assistance to the MoH, especially in setting up the dialysis outsourcing project. Dr. Karkar has great interest in clinical research and published around 100 papers in peer reviewed medical/renal journals, 7 chapters and edited 4 books in Renal Medicine, and 59 abstract publications at international conferences in Nephrology. Dr. Karkar has a great interest in hemodialysis and peritoneal dialysis and continuous renal replacement therapies. Dr. Karkar has contributed largely to the education and training of under and postgraduate medical students and nursing staff, and has organized and participated, as a speaker and/or chairperson, in many local and international congresses and symposia.

Ayman Karkar

4books edited

5chapters authored

Latest work with IntechOpen by Ayman Karkar

Hemodialysis (HD) is the commonest form of kidney replacement therapy worldwide with a prevalence rate close to 90%. Despite significant improvements in HD techniques and related devices and solutions, the cardiovascular and all-cause mortality of HD patients remains unacceptably elevated. More recently, there have been significant improvements in the creation and maintenance of vascular access as well as the knowledge of types, classification, and monitoring of uremic toxins and their relationship with inflammation, atherosclerosis and vascular classification, and cardiovascular and all-cause mortality. More interesting is the innovation in dialysis membranes/dialyzers, which resulted in the creation of the medium cut-off membrane, which enables the safe, simple, and effective removal of middle- and large-sized uremic toxins. This type of HD treatment is called expanded hemodialysis (HDx) therapy, which so far has resulted in significant improvement in the quality of life of HD patients as well as reductions in hospitalization, medications, and non-fatal cardiovascular events. Updates on Hemodialysis discusses these innovations and how they can be used to improve daily practice and achieve the best possible medical outcomes in HD patients.

Go to the book
Updates on Hemodialysis IntechOpen
Updates on Hemodialysis Edited by Ayman Karkar

Updates on Hemodialysis

Edited by Ayman Karkar

Books edited

Related collaborators